Risk-benefit of OKT3 prophylaxis in immunologic high-risk cadaver kidney transplant recipients.
Cogny-Van Weydevelt
F
F
Service de néphrologie, Hópital Maisonneuve-Rosemont, Université de Montréal, Canada.
Prud'Homme
L
L
Boucher
A
A
Dandavino
R
R
D002102:Cadaver; D003362:Cost-Benefit Analysis; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007165:Immunosuppression Therapy / Q000191:economics; D007166:Immunosuppressive Agents / Q000191:economics; D007674:Kidney Diseases / Q000628:therapy*; D016030:Kidney Transplantation / Q000276:immunology*; D016853:Muromonab-CD3 / Q000191:economics* / Q000627:therapeutic use; D010530:Peritoneal Dialysis / Q000191:economics; D016019:Survival Analysis
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3